Physician profile
Judith Olkaba
NPI 1891952875
$1,024.69
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $271 · 2021: $351 · 2022: $403.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $244.09 | 2020-2022 | |
| Corcept Therapeutics | $139.34 | 2020-2022 | |
| Biogen, INC. | $124.04 | 2021-2022 | |
| Ibsa Pharma INC. | $116.47 | 2021-2022 | |
| Novo Nordisk INC | $73.49 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $58.72 | 2021 | |
| Genzyme Corporation | $50.88 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $33.93 | 2022 | |
| Amgen INC. | $31.99 | 2020-2022 | |
| Collegium Pharmaceutical, INC. | $30.06 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $27.60 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.60 | 2022 | |
| Dexcom, INC. | $20.99 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $20.90 | 2022 | |
| Avion Pharmaceuticals | $14.83 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $13.76 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Judith Olkaba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.